Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | adrenoceptor beta 3 | Starlite/ChEMBL | References |
Homo sapiens | adrenoceptor beta 2, surface | Starlite/ChEMBL | References |
Homo sapiens | adrenoceptor beta 1 | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 5.7 | Agonist activity at human beta3 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay | ChEMBL. | 24359185 |
EC50 (binding) | = 5.7 | Agonist activity at human beta1 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay | ChEMBL. | 24359185 |
EC50 (functional) | = 8.1 | Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay | ChEMBL. | 24359185 |
Intrinsic activity (binding) | = 0.4 | Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay relative to isoprenaline | ChEMBL. | 24359185 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.